Hot Competition to Cover C-TRI, Pre-Listed Company at Kosdaq

Published: 2001-09-19 06:56:00

Updated: 2001-09-19 06:56:00

C-TRI, a bioscience corporation due to be listed at Kosdag, has been receiving so much attention from the media after being acknowledged for its growth potential.

Public opinion indicates that the significant attention generated by C-TRI is partly because of its pre-listing at Kosdaq and ma...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK